Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Immunovant, Inc.
IMVT · SEC Filings
website
315
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advanci...
Price
35.15
Market Cap
7.26 B
Float
84.83 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about IMVT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Immunovant, Inc.
IMVT · SEC Filings
84.83 M
Float
35.15
Price
7.26 B
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
NEW
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 9, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
May 20, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2025
News
TYPE
HEADLINE
FILED AT
8-K
NEW
Immunovant Reports Second Quarter Fiscal 2026 Financial Results and Corporate Updates
Nov 9, 2026
8-K
Immunovant, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Sep 3, 2026
8-K
Immunovant Reports Fiscal First Quarter 2026 Financial Results and Provides IMVT-1402 Clinical Development Update
Aug 6, 2026
8-K
Immunovant Reports Fiscal Year 2026 Financial Results and Positive Preliminary Data for IMVT-1402
May 20, 2026
8-K
Immunovant Provides Corporate and Financial Updates for Q3 2025
Feb 6, 2026
8-K
Immunovant Announces Underwritten Offering of 26.2 Million Shares at $21 Each; Roivant Participating; Closing Dec 12, 2025
Dec 12, 2025
Prospectus
TYPE
HEADLINE
FILED AT
424B5
FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $550,200,000 | Shares: 26,200,000 | Price: $21.000 | Bank: Leerink Partners
Dec 12, 2025
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]
Jan 24, 2025
424B5
7,370,000 Shares
Sep 29, 2023
424B5
Common Stock
Sep 26, 2023
424B5
12,500,000 Shares
Oct 5, 2022
424B7
988,448 Shares of Common Stock
Jan 14, 2021
Registrations
TYPE
HEADLINE
FILED AT
S-3ASR
NEW
November 2026 SHELF + ATM
Nov 9, 2026
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Dec 10, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Apr 30, 2025
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Jan 21, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Apr 15, 2024
S-3ASR
Up to $150,000,000 Common Stock PROSPECTUS Leerink Partners November 9, 2023
Nov 9, 2023
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 22, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Jul 22, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Jul 9, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 26, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Jun 26, 2024
Ownerships
TYPE
HEADLINE
FILED AT
4
Girao Tiago (Reporting)
Oct 30, 2026
4
Stout Jay S (Reporting)
Oct 23, 2026
4
Stout Jay S (Reporting)
Oct 9, 2026
4
Van Tuyl Christopher (Reporting)
Oct 9, 2026
4
Gloria Melanie (Reporting)
Oct 9, 2026
4
Venker Eric (Reporting)
Oct 5, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
LETTER
Form UPLOAD - SEC-generated letter
Feb 28, 2024
CORRESP
Form CORRESP - Correspondence
Feb 13, 2024
LETTER
Form UPLOAD - SEC-generated letter
Jan 17, 2024
LETTER
Form UPLOAD - SEC-generated letter
Feb 18, 2021
CORRESP
Form CORRESP - Correspondence
Feb 17, 2021
LETTER
Form UPLOAD - SEC-generated letter
Feb 2, 2021
